- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05930782
Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers. (PedPQP(BA/FE))
A Randomized, Open Label, Two-part, Parallel-group, Phase I Study to Evaluate the Pharmacokinetics of Piperaquine Oral Dispersible Granules Formulation Compared to Piperaquine Hard Tablets Administered as a Single Dose in Fasting Condition (Part 1) and of Piperaquine Oral Dispersible Granules Formulation Administered as Single Dose in Various Fed States (Part 2) in Healthy Adult Participants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Anne Claire Marrast, MD
- Phone Number: +41 22 555 0437
- Email: marrasta@mmv.org
Study Contact Backup
- Name: Stephan Chalon, MD, PhD
- Phone Number: +41 22 555 0379
- Email: chalons@mmv.org
Study Locations
-
-
Bagamoyo District, Pwani Region
-
Bagamoyo, Bagamoyo District, Pwani Region, Tanzania
- Ifakara Health Institute (IHI), Bagamoyo Research and Training Centre (BRTC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must fulfil all of the following criteria to be eligible for enrolment in this trial:
- Female or Male aged ≥18 years to ≤55 years at the date of signing informed consent.
- Ability to provide written, personally signed, and dated informed consent to participate in the trial, in accordance with the ICH Good Clinical Practice (GCP) and applicable regulations, before any trial-related procedures.
- An understanding, ability, and willingness to fully comply with trial procedures and restrictions.
- Female participants must agree to follow contraceptive requirements as indicated in Section 13.2.2, from at least 30 days prior to first dosage to 16 weeks after last dosage.
- Agrees not to donate sperm or ova from the time of the first administration of trial medication until twelve weeks after the end of the systemic exposure of the trial drug.
- Participants must have a body weight of 50 kg or greater and a BMI between 18.0 kg/m² - 30.0 kg/m² (inclusive) at screening.
- Satisfactory medical assessment with no clinically significant or relevant abnormalities as determined by; medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and clinical laboratory evaluation that is reasonably likely to interfere with the participant's participation in or ability to complete the trial as assessed by the Investigator.
Exclusion Criteria:
Participants will be excluded from enrolment in this trial if they fulfil any of the criteria below:
- Prior screen failure or randomisation in this trial. NOTE: Participants who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved.
- Female participant who is pregnant (from history, examination or confirmed by a positive serum pregnancy test at screening and/or on Day -1) or breastfeeding.
- Male participants with a female partner(s) who is (are) pregnant or lactating at screening and/or on Day -1, or is (are) expected to be during the trial period.
- Has a mental incapacity or language barriers precluding adequate understanding, co-operation, or compliance with the trial requirements.
- Unable or unwilling to follow a standardised diet and meal schedule or unable to fast, as required during the trial.
- Has milk intolerance.
- Unable to swallow tablets.
- Has veins on either arm that are unsuitable for intravenous puncture or cannulation (e.g., veins that are difficult to locate, or a tendency to rupture during puncture).
- Known or suspected intolerance or hypersensitivity to the investigational products, any closely related compound, or any of the stated ingredients.
- History of significant allergic reaction (e.g., anaphylaxis, angioedema) to any product (food, pharmaceutical, etc) but excluding untreated, asymptomatic, seasonal allergies.
- Donated blood or blood products (excluding plasma) within 90 days prior to trial medication administration.
- Has received or plans to receive a COVID-19 vaccination within two weeks before to one week after trial last visit.
- Treated with medication containing PQP within 90 days or five half-lives preceding the dose of trial medication (whichever is the longer).
- Ingested herbal remedies or dietary supplements containing St. John's Wort in the 30 days before the planned Day 1 of the dosing Part.
- Taking medicinal products that are known to prolong the QTc interval (see http://www.crediblemeds.org/). An up-to-date list will be in the study specific manual.
- Use of any medication that is either a moderate or strong inhibitor or inducer of CYP3A4 within 30 days or five half-lives (whichever is longer) prior to the planned day of dosing (see Drug Development and Drug Interactions, Table of Substrates, Inhibitors and Inducers, FDA). Anup to date list will be in the study specific manual.
- Use of any other prescription medication (excluding hormonal contraception and hormone replacement therapy) within 14 days or ten half-lives (whichever is longer) prior to Day 1 of the dosing Part that the Investigator judges is likely to interfere with the trial or pose an additional risk in participating.
- Use of any over-the-counter medication (including multivitamin, herbal, or homeopathic preparations; excluding paracetamol - up to 3 g of paracetamol per day permitted while participants are in-house, whereas while participants are outpatients a maximum of 1 g paracetamol per day will be allowed) during the seven days or ten half-lives of the drug (whichever is longer) prior to Day 1 of the dosing Part, that the Investigator judges is likely to interfere with the trial or pose an additional risk in participating.
- Ingested any poppy seeds within the 24 hours prior to screening or admission.
- Current use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes).
- History or clinical evidence of substance and/or alcohol abuse within the two years before screening. Alcohol abuse is defined as regular weekly intake of more than 14 units (for both males and females).
- Participants must have not consumed other substances known to be potent inhibitors or inducers of CYP34A system such as grapefruit or cranberry juice containing products in the 30 days before the planned IMP administration.
- Any history of seizures, epilepsy, photosensitivity or documented retinopathy.
- The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long QT syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events.
- Has vital signs consistently outside of the normal range at screening or Day-1.
Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of QTc interval changes. This includes participants with any of the following (at screening or Day -1):
- sinus node dysfunction
- clinically significant PR (PQ) interval prolongation (>220ms)
- second- or third-degree atrioventricular (AV) block
- sustained cardiac arrhythmia's including (but not limited to) atrial fibrillation or supraventricular tachycardia, or any symptomatic arrhythmia, with the exception of isolated extra-systoles
- abnormal T-wave morphology which may impact on the QT/QTc assessment
- QT interval corrected using the Fridericia's formula (QTcF) >450 ms
- any other ECG abnormalities in the standard 12-lead ECG or an equivalent assessment which in the opinion of the Investigator will interfere with the ECG analysis
- Participants with borderline abnormalities may be included if the deviations do not pose a safety risk, and if agreed between the appointed cardiologist and the PI.
- Positive test results for alcohol or drugs of abuse at screening or Day -1.
- Electrolyte imbalances, particularly results that are out of reference intervals for potassium, calcium or magnesium.
- Has a positive test for Hepatitis B surface Antigen (HBsAg), Hepatitis C Antibody (HCV Ab), or Human Immunodeficiency Virus Antibody (HIV Ab) at screening.
- Presence of malaria parasites by blood smear.
- Has total bilirubin, ALT or AST consistently >upper limit of normal (ULN) at screening (up to two repeats may be taken during the screening period; participants may be included if two out of the three total results are ≤ULN), or has total bilirubin >ULN on Day -1 (mild variations from baseline may be allowed if considered not clinically significant by the Investigator).
- Has a haemoglobin, platelet count, total white blood cell count, lymphocyte or monocyte count < lower limit of normal (LLN) (up to two repeats may be taken during the screening period and on Day -1 (participants may be included if two out of the three total results are greater or equal to LLN), at screening. Where there is a clear diurnal effect on the result participants may be included if variations are considered not clinically relevant by the Investigator.
- Current or recurrent disease (e.g., cardiovascular, haematological, neurological, endocrine, immunological, renal, hepatic or gastrointestinal or other conditions, including cholecystectomy or gastrectomy) that could affect the action, absorption, distribution, metabolism or excretion of PQP or could affect clinical assessments or clinical laboratory evaluations.
- Current or relevant history of physical or psychiatric illness that are not stable or may require a change in treatment, or use of prohibited therapies during the trial,that make the participant unlikely to fully comply with the requirements of the trial or to complete the trial, or any condition that presents undue risk from the investigational product or trial procedures.
- Any other abnormal findings on vital signs, ECG, physical examination or laboratory assessments that the Investigator judges as likely to interfere with the trial or pose an additional risk in participating.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.
- Any conditions which in the opinion of the Investigator would make the participant unsuitable for enrolment or could interfere with the participation in or completion of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Part 1 (fasted) : Group 1 PQP hard tablet, 320mg (N=12)
Group 1: Piperaquine hard tablet, 320mg (administered in fasting condition of at least 10 hours) (N=12)
|
PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
|
Experimental: Part 1 (Fasted): Group 2: PQP dispersible granules 320mg (N=12)
Group 2: Piperaquine dispersible granules 320mg administered in fasting condition of at least 10 hours (N=12)
|
PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
|
Experimental: Part 2 (Fed): Group 3 - high fat: PQP dispersible granule (planned as 320 mg) (N=12)
Group 3: Piperaquine dispersible granules 320mg administered in fed conditions - High-fat meal (N=12)
|
PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
|
Experimental: Part 2 Fed): Group 4 - low fat: PQP dispersible granule (planned as 320 mg) (N=12)
Group 4: Piperaquine dispersible granules 320mg administered in fed conditions - Low-fat meal representative of African diet (N=12)
|
PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
|
Experimental: Part 2 (Fed): Group 5 - whole milk: PQP dispersible granule (planned as 320 mg) (N=12)
Group 5: Piperaquine dispersible granules 320mg administered in fed conditions - Whole milk 250 ml (N=12)
|
PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative bioavailability (Frel) of the Maximum Observed Plasma Concentration (Cmax) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel Cmax).
Time Frame: Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Blood samples are analysed for PQP concentrations at the indicated time points to determine the maximum observed plasma concentration (Cmax) for PQP dispersible granule (test) and PQP hard tablet (reference) in the fasted state.
Pharmacokinetic parameters are determined using standard non-compartmental analysis.
Frel Cmax is calculated as the ratio of Cmax of the PQP dispersible granule compared to the PQP hard tablet in the fasted state.
|
Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to 72h hours (AUC0-72h) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-72h).
Time Frame: Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Blood samples are analysed for PQP concentrations at the indicated time points to calculate the area under the plasma concentration-time curve from time zero to 72 hours (AUC0-72h) for PQP dispersible granule (test) and PQP hard tablet (reference) in the fasted state.
Pharmacokinetic parameters are determined using standard non-compartmental analysis.
Frel AUC0-72h is calculated as the ratio of AUC0-72h of the PQP dispersible granule compared to the PQP hard tablet in the fasted state.
|
Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to the last quantifiable concentration (AUC0-t) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-t).
Time Frame: Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Blood samples are analysed for PQP concentrations at the indicated time points to calculate the area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) for PQP dispersible granule (test) and PQP hard tablet (reference) in the fasted state.
Pharmacokinetic parameters are determined using standard non-compartmental analysis.
Frel AUC0-t is calculated as the ratio of AUC0-t of the PQP dispersible granule compared to the PQP hard tablet in the fasted state.
|
Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to 168 hours (AUC0-168h) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-168h.
Time Frame: Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Blood samples are analysed for PQP concentrations at the indicated time points to calculate the area under the plasma concentration-time curve from time zero to 168 hours (AUC0-168h) for PQP dispersible granule (test) and PQP hard tablet (reference) in the fasted state.
Pharmacokinetic parameters are determined using standard non-compartmental analysis.
Frel AUC0-168h is calculated as the ratio of the AUC0-168h of the PQP dispersible granule compared to the PQP hard tablet in the fasted state.
|
Plasma samples taken pre-dose -0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero extrapolated to infinity (AUC0-∞) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-∞).
Time Frame: Plasma samples taken pre-dose 0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Blood samples are analysed for PQP concentrations at the indicated time points to calculate the area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) for PQP dispersible granule (test) and PQP hard tablet (reference) in the fasted state.
Pharmacokinetic parameters are determined using standard non-compartmental analysis.
Frel AUC0-∞ is calculated as the ratio of the AUC0-∞ of the PQP dispersible granule compared to the PQP hard tablet in the fasted state.
|
Plasma samples taken pre-dose 0.5 hours, then 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, Day 5, Day 8, Day 15, Day 22 and Day 30 post-dose.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florence A Milando, MD, MPH, Ifakara Health Institute (IHI), Tanzania
- Study Director: Said A Jongo, MD, MMed, PhD, Ifakara Health Institute (IHI), Tanzania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMV_SMC_22_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Piperaquine Phosphate
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Department of Medical Research...WithdrawnUncomplicated Falciparum Malaria | Artemisinin-resistant
-
Novartis PharmaceuticalsMedicine for Malaria VentureTerminatedPlasmodium Falciparum MalariaAustralia
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaboratorsCompleted
-
Ifakara Health InstituteCompletedMalaria, Falciparum | Plasmodium FalciparumTanzania
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, SenegalCompleted
-
Papua New Guinea Institute of Medical ResearchUniversity of Melbourne; The University of Western Australia; Malaria in Pregnancy...UnknownPregnancy | Clinical Efficacy | Drug Kinetics | Infections, PlasmodiaPapua New Guinea
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Richard MwaisweloNational Institute for Medical Research, Tanzania; Muhimbili University of... and other collaboratorsCompletedMalaria | Chemoprophylaxis | Underfive ChildrenTanzania
-
Menzies School of Health ResearchWorld Health Organization; Eijkman Institute for Molecular BiologyCompletedPlasmodium Falciparum Infection | Plasmodium Vivax InfectionIndonesia